Millie
your market intelligence analyst
Search Results
32 results
Your search is now limited to «Leukemia» expert search.
ClinicalTrials.gov 07/23/2019 08:07
Conditions : CD19 Positive; CD22 Positive; Minimal Residual Disease; Progressive Disease; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin Lymphoma Interventions : Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors : M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting.
ClinicalTrials.gov 07/23/2019 08:06
Conditions : Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse; Non-Hodgkin's Lymphoma Refractory; Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic; B-cell Chronic Lymphocytic Leukemia; B-cell Non Hodgkin Lymphoma Interventions : Genetic: PBCAR20A; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor : Precision BioSciences, Inc. Not yet recruiting.
ClinicalTrials.gov 07/23/2019 07:03
Following MTD/MAD identification, three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) will be conducted to identify the recommended Phase 2 dose (RP2D) of idasanutlin in each combination, with chemotherapy or venetoclax.
Healio News 07/21/2019 08:00
CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about the ZUMA-3 study. The phase 1/phase 2 study evaluated KTE-X19 (Kite Pharma), an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed/refractory acute lymphoblastic leukemia. Shah provided an overview of end-of-phase-1 results. “We were able to identify a cell dose and a toxicity management algorithm that seems to come with highly encouraging response rates and highly.
ClinicalTrials.gov 07/19/2019 06:50
Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML.
PubMed News (NIH) 07/19/2019
Status Public on Jul 19, 2019 Title Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection Organism Homo sapiens Experiment type Expression profiling by high throughput sequencing Summary Chemotherapy-resistant cancer recurrence is a major cause of mortality.

Energy

Business Issues

Companies - Public

Companies - Venture Funded

Chemicals - Agricultural

Chemicals - Industrial

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications